Australia’s medical research community is in limbo after a cyberattack took down the ANZ Clinical Trials Registry (ANZCTR), a ...

Researchers have been unable to register trials with the Australian New Zealand Clinical Trials Registry for more than a week after a cyberattack.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Parliamentary Panel calls for setting up of a platform CTMS for Ayush clinical research: Gireesh Babu, New Delhi Wednesday, March 19, 2025, 08:00 Hrs [IST] The Parliamentary Panel ...

Investigators should be aware that studies that meet the definition of clinical trial may be subject to additional regulatory and/or policy requirements, such as posting of consent forms on federal ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm ...

Pharos iBio announced on the 21st that it has signed a memorandum of understanding (MOU) for the development of companion ...

However, sponsors can remedy that situation using freely available tools such as TransCelerate’s Clinical Trial Registration Tool. This solution allows sponsors to copy and paste a protocol ...

Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...

Prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for ...